vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $129.7M, roughly 1.2× Travere Therapeutics, Inc.). On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 73.4%).
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
STOK vs TVTX — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $129.7M |
| Net Profit | $112.9M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 70.2% | -25.0% |
| Net Margin | 71.2% | — |
| Revenue YoY | 3661.1% | 73.4% |
| Net Profit YoY | 528.0% | — |
| EPS (diluted) | $1.90 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $129.7M | ||
| Q3 25 | — | $164.9M | ||
| Q2 25 | — | $114.4M | ||
| Q1 25 | $158.6M | $81.7M | ||
| Q4 24 | $22.6M | $74.8M | ||
| Q3 24 | — | $62.9M | ||
| Q2 24 | — | $54.1M | ||
| Q1 24 | — | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $25.7M | ||
| Q2 25 | — | $-12.8M | ||
| Q1 25 | $112.9M | $-41.2M | ||
| Q4 24 | $-10.5M | — | ||
| Q3 24 | — | $-54.8M | ||
| Q2 24 | — | $-70.4M | ||
| Q1 24 | — | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | -11.1% | ||
| Q1 25 | 70.2% | -52.2% | ||
| Q4 24 | -60.4% | -81.2% | ||
| Q3 24 | — | -89.3% | ||
| Q2 24 | — | -125.1% | ||
| Q1 24 | — | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 15.6% | ||
| Q2 25 | — | -11.1% | ||
| Q1 25 | 71.2% | -50.4% | ||
| Q4 24 | -46.4% | — | ||
| Q3 24 | — | -87.1% | ||
| Q2 24 | — | -130.1% | ||
| Q1 24 | — | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $0.28 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | $1.90 | $-0.47 | ||
| Q4 24 | $-0.15 | $-0.71 | ||
| Q3 24 | — | $-0.70 | ||
| Q2 24 | — | $-0.91 | ||
| Q1 24 | — | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $350.1M | $114.8M |
| Total Assets | $406.9M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | $274.8M | $61.9M | ||
| Q4 24 | $128.0M | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | — | $114.8M | ||
| Q3 25 | — | $73.6M | ||
| Q2 25 | — | $32.7M | ||
| Q1 25 | $350.1M | $32.8M | ||
| Q4 24 | $229.0M | $59.1M | ||
| Q3 24 | — | $-30.5M | ||
| Q2 24 | — | $15.1M | ||
| Q1 24 | — | $74.1M |
| Q4 25 | — | $605.2M | ||
| Q3 25 | — | $538.6M | ||
| Q2 25 | — | $555.3M | ||
| Q1 25 | $406.9M | $548.8M | ||
| Q4 24 | $271.6M | $594.1M | ||
| Q3 24 | — | $504.4M | ||
| Q2 24 | — | $551.1M | ||
| Q1 24 | — | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | $60.7M |
| Free Cash FlowOCF − Capex | $131.7M | — |
| FCF MarginFCF / Revenue | 83.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.7M | ||
| Q3 25 | — | $14.3M | ||
| Q2 25 | — | $5.0M | ||
| Q1 25 | $131.8M | $-42.2M | ||
| Q4 24 | $-23.2M | $-35.7M | ||
| Q3 24 | — | $-42.5M | ||
| Q2 24 | — | $-40.2M | ||
| Q1 24 | — | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | $131.7M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | 83.0% | — | ||
| Q4 24 | -102.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STOK
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
